Published Research and Presentations

Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant (M0 CRPC) prostate cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201)

Other

ASCO GU 2025

14/02/2025

TRIALS IN PROGRESS –P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours

P3BEP

ASCO GU 2025

14/02/2025

Gemcitabine-Docetaxel Intravesical instillation Synchronous CO-administration-A phase I study: G-DISCO (ANZUP 2403)

Other

ASCO GU 2025

14/02/2025

Kevin G. Keane, Cynthia Hawks, Stephen P. McCombie, Ek Leone Oh, Andrew D. Redfern, Dickon Hayne

SUB-urothelial DUrvalumab-zirconium to investigatE local and systemic distribution of durvalumab when injected in the sub-urothelium: SUBDUE-3 (ANZUP 2402)

Other

ASCO GU 2025

14/02/2025

Kevin G. Keane, Andrisha J. Inderjeeth, Roslyn J. Francis, Andrew M. Scott, Cynthia Hawks, Richard Gauci, Ian D. Davis, Andrew D. Redfern, Dickon Hayne

Estimating Treatment Effects After a Positive Initial Interim Analysis: Challenges and Considerations

ENZAMET

ACTA 2024

03/12/2024

Yu Yang Soon, Ian Marschner, Manjula Schou, Christopher J Sweeney, Ian D. Davis, Martin Stockler, Andrew Martin

Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)

ENZAMET

ESMO 2024

16/09/2024

Lisa G Horvath, Hui-Ming Lin, Ian D Davis, Andrew J Martin, Tahlia Scheinberg, Neil Portman, Peter J Meikle, Kevin Huyn, Anthony Joshua, Margaret McJannett, Vinod Subhash, Sonia Yip, Scott A North, Raymond S McDermott, Kim N Chi, Martin R Stockler, Christopher Sweeney for the ENZAMET trial investigators on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).

Clinical prognostic factors within the high volume (HV) subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)

ENZAMET

16/09/2024

Anis A Hamid, Hayley Thomas, Andrew Martin, Yu Yang Soon, Lisa Horvath, Robert Zielinski, Alastair Thomson, T Hsiang Tan, Shahneen Sandhu, M Neil Reaume, David Pook, Francis Parnis, Ray McDermott, Nicola J Lawrence, Mark Frydenberg, Kim Chi, Martin R Stockler, Ian D Davis, Christopher J Sweeney

Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [ 177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)

TheraP

03/06/2024

Edmond M. Kwan, Michael S. Hofman, Sarah W.S. Ng, Louise Emmett, Shahneen Sandhu, James P. Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Vinod Subhash, Sze-Ting Lee, Andrew M. Scott, Andrew J. Marting,j, Martin R. Stockler, Grainne Donnellan, Matti Annala, Sofie H. Tolmeijer, Arun A. Azad, Ian D. Davis,, Alexander W. Wyatt

PSA at 7 months is prognostic in metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide: landmark analysis of ENZAMET (ANZUP 1304)

ENZAMET

03/06/2024

Ronan A. McLaughlin, Hayley Thomas, Ian D. Davis, Robert R. Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume8, David W. Pook Francis Parnis, Scott A. North, Gavin M. Marx, John McCaffrey, Raymond S. McDermott, Lisa Horvath, Mark Frydenberg, Simon Chowdhury, Kim N. Chi, Martin R. Stockler, Christopher J. Sweeney

UNICAB: Cabozantinib In Locally Advanced Or Metastatic Non‐Clear Cell Renal Cell Carcinoma Post Immunotherapy or in those Unsuitable For Immunotherapy (ANZUP 1802)

UNICAB

ASCO 2024

29/01/2024

David W. Pook, Carole A. Harris, Emma Link, Jeffrey C. Goh, Francis Parnis, Howard Gurney, Ganessan Kichenadasse, Craig Underhill, Javier Torres, Felicia Roncolato, Andrisha-Jade Inderjeeth, Ciara Conduit, Margaret M. McJannett, Ian D. Davis, Craig Gedye